Deferasirox for managing iron overload in people with thalassaemia

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2012, Pages

  Meerpohl, Joerg J ^a   Antes, Gerd ^a   Rücker, Gerta ^a   Fleeman, Nigel ^b   Motschall, Edith ^a   Niemeyer, Charlotte M ^a   Bassler, Dirk ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; DEFERASIROX; DEFEROXAMINE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ERYTHROCYTE TRANSFUSION; HUMAN; IRON OVERLOAD; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THALASSEMIA;

BENZOIC ACIDS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALASSEMIA; TRIAZOLES;

EID: 84861323685     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007476.pub2     Document Type: Review

References (115)

1. Angelucci E, Turlin B, Canatan D, Mangiagli A, De Sanctis V, Meddeb B, et al.Iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood 2005;106(11 Pt 1):Abstract no: 2696.
2. Brissot P, Turlin B, Forni GL, Alimena G, Quarta G, Selleslag D, et al.Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia [abstract]. Blood 2005;106(11):Abstract no: 823.
3. Cappellini M, Bejaoui M, Perrotta S, Agaoglu L, Kattamis A, Giardina P, et al.Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis. Blood 2004;104(11 Pt 1):Abstract no: 3619.
4. Cappellini MD, Bejaoui M, Agaoglu L, Lai ME, Mangiagli A, Strauss G, et al.Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]. Blood 2005;106(11):Abstract no: 2704.
5. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al.Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clinical Therapeutics 2007;29(5):909-17.
6. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al.A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62.
7. Cappellini MD, Giardina P, Porter J, Coates T, Della Porta MG, Siegal J, et al.Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. [abstract]. Blood 2006;108(11):Abstract no: 1768.
8. Christoforidis A, Tsatra I, Karasmanis K, Zevgaridou E, Koussi A, Tsitourides I, et al.Evaluation of myocardial deposition assessed with M.R.I in young thalassaemic patients receiving one year of deferasirox versus deferoxamine [abstract]. Haematologica 2006;91(S1):209.
9. Cohen A, Masera G, Zoumbos N, Uysal Z, Boulet D, Watman N, et al.Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670) [abstract]. Blood 2005;106(11 Pt 1):Abstract no: 822.
10. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111(2):583-7.
11. Deugnier Y, Turlin B, Ropert M, Bejaoui M, Athanassiou-Metaxa M, Cario H, et al.Semi-quantitative assessment of hemosiderin distribution accurately reflects reductions in liver iron concentration following therapy with deferasirox (Exjade (R), ICL670) or deferoxamine in patients with transfusion-dependent anemia. Blood 2005;106(11 Pt 1):761A.
12. Deugnier Y, Turlin B, Ropert-Bouchet M, Rabault B, Brissot P. Effect of iron chelation therapy with deferasirox (Exjade (R), ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion-dependent anemia. Journal of Hepatology 2008;48(Suppl 2):S79-80.
13. Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration?. Blood 2006; Vol. 108, issue 5:1775-6; author reply 1776. [PUBMED: 16926297].
14. Galanello R. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences 2005:183-5.
15. Grosse R, Janssen G, Engelhardt R, Groeger M, Leismann O, Nielsen P, Fischer R. Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry [abstract]. Blood 2006;108(11):Abstract number: 1779.
16. Karnon J, Akehurst RL, Jewitt K, Ossa D. Cost utility analysis deferasirox versus deferoxamine (desferal) for patients requiring iron chelation therapy in the United Kingdom [abstract]. Haematologica 2007;92 Suppl 1:222.
17. Kattamis A, Paley C, Study Investigators. Iron chelating efficacy is related to transfusional iron intake in pediatric patients-treated with deferasirox(Exjade (R), ICL670). Pediatric Blood & Cancer 2007;48(6):609.
18. Kattamis C, Kilinc Y, Fattoum S, Ferster A, Gallisai D, Maggio A, et al.Deferasirox (Exjade (R), ICL670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients. Blood 2005;106(11 Pt 1):756A, Abstract no: 2692.
19. Kattamis C, Meddeb B, Ressayre-Djaffer C, Alberti D, Parsing Using Smart Source. Baseline iron studies demonstrate severe iron overload in patients enrolled into the deferasirox (Exjade(R), ICL670) clinical trial programme [abstract]. Haematologica 2006;91(Suppl 1):415.
20. Kleinert DA, Jones E, Sison CP, Marks P, Giardina PJ. Left ventricular cardiac function during the course of a one year multicenter trial of the safety and efficacy with ICL670 5-40mg/kg/day and deferoxamine 20-60 mg/kg/day in beta-thalassemia patients with transfusional hemosideosis. Blood 2005;106(11 Pt 2):44B Abstract no: 3853.
21. Martin MG, Arcasoy MO. Deferasirox versus deferoxamine. Blood 2006;108(2):774-5; author reply 775-6. [PUBMED: 16822908].
22. Piga A, Fischer R, Harmatz P, St Pierre T G, Longo F, Fung E, et al.Comparison of LIC obtained from biopsy, BLS and R-2-MRI in iron overloaded patients with beta-thalassemia, treated with deferasirox (Exjade (R), ICL670). Blood 2005;106(11 Pt 1):755A.
23. Walter P, Macklin E, Porter J, Evans P, Coates T, Olivieri NF, et al.Control of oxidant-stress and inflammation by iron chelators Deferasirox (ICL670) or Deferoxamine in beta-thalassaemia: an ancillary study of the Novartis CICL670A0107 Trial [abstract]. Blood 2005;106(11):Abstract no: 3598.
24. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al.Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008;93(6):817-25.
25. Walter PB, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, et al.Leukocyte apoptosis and mitochondrial dysfunction in beta-thalassemia patients treated with deferasirox or deferoxamine. Blood 2007;110(11 Pt 1):815A, Abstract no: 2773.
26. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. Journal of Clinical Pharmacology 2003;43(6):565-72.
27. Piga A, Galanello R, Dessi C, Sedaro M, Loehrer F, Schaud R, et al.A novel oral iron chelator (ICL670A): results of a phase I single-dose safety study [abstract]. Blood 1999;10(Suppl 1 Pt 2):35b.
28. Giardina P, Olivieri NF, Nisbet-Brown E, Grady RW, Sizer KC, Sechaud R, et al.ICL670, a tridentate orally-active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia [abstract]. 7th Congress of the European Hematology Association; 2002 June 6-9; Florence, Italy. 2002:Abstract no: 0236.
29. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al.Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361(9369):1597-602.
30. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Sizer K, Sechaud R, et al.ICL670A, a tridentate orally-active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia. [abstract]. Blood 2001;98(11 Pt 1):747a.
31. Cappellini M, Galanello R, Piga A, Forni GL, Zanaboni L, Muroni P, et al.Update on the effects of icl670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload [abstract]. Proceedings of the 7th Meeting of the European Hematology Association, Florence, Italy, 6-9 June, 2002. 2002, issue Suppl 1:184.
32. Cappellini MD, Galanello R, Piga A, Forni GL, Opitz H, Ford JM, et al.Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a phase II study in patients with transfusional hemosiderosis. 8th Congress of the European Hematology Association, Lyon, France. Lyon, 2003.
33. Piga A, Galanello R, Cappellini M, Forni GL, Opitz H, Ford JM, et al.Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy [abstract]. Blood 2002;100(11 Pt 1):5a.
34. Piga A, Galanello R, Cappellini MD, Forni GL, Lupo G, Ford JM, et al.Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy [abstract]. Blood 2003;102(11):Abstract no: 412.
35. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al.Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91(7):873-80.
36. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95(4):557-66. [PUBMED: 19951979].
37. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, et al.Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia research 2010;34(9):1143-50. [PUBMED: 20451251].
38. Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, et al.Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. European journal of haematology 2009;82(6):454-7. [PUBMED: 19191863].
39. Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Annals of hematology 2010;89(4):405-9. [PUBMED: 19798501].
40. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al.Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematologica 2010;123(4):220-5. [PUBMED: 20424435].
41. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al.Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. European Journal of Haematology 2009;82(6):458-65. [PUBMED: 19187278].
42. Evaluating use of deferasirox as compared to deferoxamine in treating cardiac iron overload.. Ongoing study Study start date: November 2007Estimated primary completion date: December 2010 (Final data collection date for primary outcome measure).
43. Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Annals of the New York Academy of Sciences 1998;850:251-69.
44. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, et al.Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93(5):741-52. [PUBMED: 18413891].
45. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al.Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93.
46. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al.Survival and complications in thalassemia. Annals of the New York Academy of Sciences 2005;1054:40-7.
47. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al.Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. The New England Journal of Medicine 1994;331(9):567-73.
48. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Seminars in Hematology 2005;42(2 Suppl 1):S19-21.
49. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al.A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62.
50. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al.Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clinical Therapeutics 2007;29(5):909-17.
51. Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Reviews 2008;22 Suppl 2:S35-41. [PUBMED: 19059055].
52. Cappellini MD, Pattoneri P. Oral iron chelators. Annual Review of Medicine 2009;60:25-38. [PUBMED: 19630568].
53. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, et al.The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology 2002;118(1):330-6.
54. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, et al.Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009;114(19):4009-13. [PUBMED: 19724055].
55. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Transactions of the American Pediatric Society 1925;37:29-30.
56. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine 2002;21(15):2131-44.
57. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine 2002;21(15):2145-59.
58. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Statistics in Medicine 2002;21(15):2161-73.
59. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004;104(1):263-9. [PUBMED: 15001468].
60. Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology 2008;83(4):263-70.
61. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
62. European Medicines Agency, London, UK. Exjade: European Public Assessment Report: Summary of Product Characteristics. www.emea.europa.eu/humandocs/Humans/EPAR/exjade/exjade.htm (accessed 14 February 2008).
63. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. British Journal of Haematology 2006;134(4):438-44.
64. Food, Drug Administration (FDA). USA. Exjade. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021882s010lbl.pdf (accessed 02 September 2011).
65. US Food, Drug Administraton. Exjade (Deferasirox): Boxed Warning. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm200850.htm (accessed 02 September 2011).
66. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. American Journal of Diseases of Children 1990;144(5):565-9.
67. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996;95(1):26-36.
68. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, et al.A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91(9):1241-3.
69. Grange S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2010;25(7):2376-8. [PUBMED: 20466673].
70. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
71. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
72. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester, UK: John Wiley & Sons, Ltd, 2011.
73. Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NT, Kontoghiorghes GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989;2(8660):457.
74. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102(1):17-24.
75. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88(12):1423-25.
76. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008;32(1-2):41-7.
77. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al.Effective chelation of iron in beta thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. BMJ (Clinical Research Edition) 1987;295(6612):1509-12.
78. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1, 2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1(8545):1294-95.
79. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. International Journal of Hematology 1991;54(5):371-5.
80. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology / the Education Program of the American Society of Hematology 2001;1:47-61. [DOI: 10.1182/asheducation-2001.1.47].
81. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clinical Therapeutics 2007;29(10):2154-66. [PUBMED: 18042472].
82. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al.Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Molecules and Diseases 2002;28(2):196-208.
83. McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, et al.Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2009;13(1):iii-iv, ix-xi, 1-121. [PUBMED: 19068191].
84. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355(9220):2051-2.
85. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86(6):480-7.
86. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al.Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361(9369):1597-602.
87. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al.Survival in medically treated patients with homozygous beta-thalassemia. The New England Journal of Medicine 1994;331(9):574-8.
88. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(3):739-61.
89. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al.Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. The New England Journal of Medicine 1998;339(7):417-23.
90. Olivieri NF. The beta-thalassemias. The New England Journal of Medicine 1999;341(2):99-109.
91. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al.Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90(10):1309-14.
92. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
93. Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin 2008;32(1-2):49-62.
94. Porter JB. Deferasirox: an update. Hemoglobin 2009;33 Suppl 1:S70-5. [PUBMED: 20001635].
95. Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M. Fanconi syndrome due to deferasirox. American journal of kidney diseases: the official journal of the National Kidney Foundation 2009;54(5):931-4. [PUBMED: 19493602].
96. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
97. Richer J, Chudley AE. The hemoglobinopathies and malaria. Clinical Genetics 2005;68(4):332-6.
98. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004450.pub2].
99. Roberts DJ, Brunskill S, Doree C, Williams S, Howard J, Hyde C. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004839.pub2].
100. Rund D, Rachmilewitz E. Beta-thalassemia. The New England Journal of Medicine 2005;353(11):1135-46.
101. Scottish Intercollegiate Guidelines Network. A guideline developer's handbook. Guideline No. 50. http://www.sign.ac.uk/guidelines/fulltext/50/index.html (accessed 02 September 2011).
102. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells, Molecules & Diseases 2006;37(1):12-20.
103. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al.Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. British journal of haematology 2009;147(5):752-9.
104. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al.Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta haematologica 2010;123(4):220-5. [PUBMED: 20424435].
105. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al.A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115(14):1876-84.
106. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al.Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American journal of hematology 2011;86(5):433-6.
107. Vanorden HE, Hagemann TM. Deferasirox--an oral agent for chronic iron overload. Annals of Pharmacotherapy 2006;40(6):1110-7.
108. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al.Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100(5):1566-9.
109. Weatherall DJ. Thalassemia in the next millennium. Keynote address. Annals of the New York Academy of Sciences 1998; Vol. 850:1-9.
110. Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 4th Edition. Oxford: Blackwell Sciences Ltd., 2000.
111. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(22):3337-51.
112. Witte S, Victor N. Some problems with the investigation of noninferiority in meta-analysis. Methods of Information in Medicine 2004;43(5):470-4.
113. Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 2006;30(2):215-8.
114. Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology (Carlton, Vic.) 2010;15(3):377. [PUBMED: 20470310].
115. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al.Survival and causes of death in thalassaemia major. Lancet 1989;2(8653):27-30.